This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Glaxosmithkline LLC. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Celebrating the Innovations of Jeffrey Gaulding
Introduction: Jeffrey Gaulding, an inventive mind based in Tucker, Georgia, has made significant contributions to the field of pharmaceuticals. With a focus on developing advanced compounds, he holds a notable patent that reflects his expertise and dedication to innovation in medicinal chemistry.
Latest Patents: Gaulding's most prominent patent is titled "Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamic hydrochloride." This invention is an improved AKT inhibiting compound that presents a crystalline structure, enhancing its properties and potential applications in therapeutic settings.
Career Highlights: Gaulding is affiliated with GlaxoSmithKline LLC, a globally recognized pharmaceutical company. His role there has allowed him to contribute to the development of innovative drugs that address critical health issues. Gaulding’s patent showcases his ability to merge scientific research with practical applications, reinforcing his standing as a prominent inventor in his field.
Collaborations: Throughout his career, Gaulding has collaborated with talented professionals, including his coworker Pingyun Chen. These collaborative efforts highlight the importance of teamwork in the innovation process, as they work together to advance their projects and contribute to groundbreaking discoveries.
Conclusion: Jeffrey Gaulding's contributions to pharmaceutical innovations exemplify the spirit of creativity and dedication in research and development. His patent, which focuses on a significant advancement in AKT inhibiting compounds, marks him as a valuable inventor in the biomedical landscape. Through his work at GlaxoSmithKline and collaborations with colleagues, Gaulding continues to push the boundaries of what is possible in pharmaceuticals, ultimately enhancing therapeutic options for patients worldwide.